Organon & Co. Effective Tax Rate
Organon & Co. (OGN) reported Effective Tax Rate of 41.30% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-07-31
- Organon & Co. effective income tax rate reconciliation, percent for the quarter ending 2026-06-30 was 41.30%, a 11.62% increase year-over-year.
- Organon & Co. effective income tax rate reconciliation, percent for the quarter ending 2026-03-31 was 31.40%, a 134.33% increase year-over-year.
- Organon & Co. effective income tax rate reconciliation, percent for the quarter ending 2025-09-30 was 34.00%.
- Organon & Co. effective income tax rate reconciliation, percent for the quarter ending 2025-06-30 was 37.00%, a 113.87% increase year-over-year.
- Organon & Co. effective income tax rate reconciliation, percent for fiscal 2025 was 56.00%.
- Organon & Co. effective income tax rate reconciliation, percent for fiscal 2024 was -7.10%.
- Organon & Co. effective income tax rate reconciliation, percent for fiscal 2023 was -52.20%, a 385.25% decline from fiscal 2022.
- Organon & Co. effective income tax rate reconciliation, percent for fiscal 2022 was 18.30%, a 56.41% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month |
|---|---|---|---|---|
| 2026-06-30 | 41.30% 10-Q · filed 2026-07-31 | 36.00% 10-Q · filed 2026-07-31 | ||
| 2026-03-31 | 31.40% 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | 56.00% 10-K · filed 2026-02-24 | |||
| 2025-09-30 | 34.00% 10-Q · filed 2025-11-10 | 31.60% 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | 37.00% 10-Q · filed 2026-07-31 | 29.80% 10-Q · filed 2026-07-31 | ||
| 2025-03-31 | 13.40% 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | -7.10% 10-K · filed 2026-02-24 | |||
| 2024-09-30 | -73.70% 10-Q · filed 2025-11-10 | -11.30% 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | 17.30% 10-Q · filed 2025-08-06 | 16.00% 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | 14.70% 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | -52.20% 10-K · filed 2026-02-24 | |||
| 2023-09-30 | 27.00% 10-Q · filed 2024-11-01 | 16.10% 10-Q · filed 2024-11-01 | ||
| 2023-06-30 | 5.00% 10-Q · filed 2024-08-07 | 14.40% 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | 24.60% 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | 18.30% 10-K/A · filed 2025-11-10 | |||
| 2022-09-30 | 19.60% 10-Q · filed 2023-11-03 | 20.00% 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | 18.50% 10-Q · filed 2023-08-09 | 20.20% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 21.30% 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | 11.70% 10-K · filed 2024-02-26 | |||
| 2021-09-30 | 17.10% 10-Q · filed 2022-11-04 | 11.20% 10-Q · filed 2022-11-04 | ||
| 2021-06-30 | 1.40% 10-Q · filed 2022-08-05 | 8.60% 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | 15.50% 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | 18.00% 10-K · filed 2023-02-27 | |||
| 2020-09-30 | 17.80% 10-Q · filed 2021-11-12 | 15.60% 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | 16.50% 10-Q · filed 2021-08-16 | 14.60% 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | 13.00% 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | 10.60% 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |